A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL TO COMPARE THE SAFETY AND IMMUNOGENICITY OF RECOMBINANT ENVELOPE PROTEIN RGP120/HIV-1SF2 (BIOCINE) COMBINED WITH SEVEN ADJUVANTS IN HEALTHY HIV-1 UNINFECTED INDIVIDUALS: